BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33852336)

  • 1. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: Radiologic and Clinical Factors Predictive of Survival.
    Kim B; Won JH; Kim J; Kwon Y; Cho HJ; Huh J; Kim JK
    AJR Am J Roentgenol; 2021 Jun; 216(6):1566-1573. PubMed ID: 33852336
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy.
    Oh MJ; Lee HJ; Lee SH
    Clin Mol Hepatol; 2013 Sep; 19(3):288-99. PubMed ID: 24133667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma.
    Kim BK; Park JY; Choi HJ; Kim DY; Ahn SH; Kim JK; Lee DY; Lee KH; Han KH
    J Cancer Res Clin Oncol; 2011 Apr; 137(4):659-67. PubMed ID: 20552225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma.
    Song MJ; Bae SH; Chun HJ; Choi JY; Yoon SK; Park JY; Han KH; Kim YS; Yim HJ; Um SH; Chung WJ; Hwang JS; Cho SB; Eun JR
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):739-46. PubMed ID: 25663125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.
    Lee BH; Lee DS; Cho CW; Yun SS
    World J Surg Oncol; 2019 Aug; 17(1):143. PubMed ID: 31416447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
    Park JY; Ahn SH; Yoon YJ; Kim JK; Lee HW; Lee DY; Chon CY; Moon YM; Han KH
    Cancer; 2007 Jul; 110(1):129-37. PubMed ID: 17508408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
    Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
    BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.
    Kim HY; Kim JD; Bae SH; Park JY; Han KH; Woo HY; Choi JY; Yoon SK; Jang BK; Hwang JS; Kim SG; Kim YS; Seo YS; Yim HJ; Um SH;
    Korean J Hepatol; 2010 Dec; 16(4):355-61. PubMed ID: 21415578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
    Ando E; Tanaka M; Yamashita F; Kuromatsu R; Yutani S; Fukumori K; Sumie S; Yano Y; Okuda K; Sata M
    Cancer; 2002 Aug; 95(3):588-95. PubMed ID: 12209752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
    Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy.
    Niizeki T; Sumie S; Torimura T; Kurogi J; Kuromatsu R; Iwamoto H; Aino H; Nakano M; Kawaguchi A; Kakuma T; Sata M
    J Gastroenterol; 2012 Jun; 47(6):686-95. PubMed ID: 22382631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    He M; Li Q; Zou R; Shen J; Fang W; Tan G; Zhou Y; Wu X; Xu L; Wei W; Le Y; Zhou Z; Zhao M; Guo Y; Guo R; Chen M; Shi M
    JAMA Oncol; 2019 Jul; 5(7):953-960. PubMed ID: 31070690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy.
    Shao YY; Liang PC; Wu YM; Huang CC; Huang KW; Cheng JC; Hsu CH; Hsu C; Cheng AL; Lin ZZ
    Liver Int; 2013 Oct; 33(9):1413-9. PubMed ID: 23714197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
    Yamasaki T; Kimura T; Kurokawa F; Aoyama K; Ishikawa T; Tajima K; Yokoyama Y; Takami T; Omori K; Kawaguchi K; Tsuchiya M; Terai S; Sakaida I; Okita K
    J Gastroenterol; 2005 Jan; 40(1):70-8. PubMed ID: 15692792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Automatic prediction of hepatic arterial infusion chemotherapy response in advanced hepatocellular carcinoma with deep learning radiomic nomogram.
    Xu Z; An C; Shi F; Ren H; Li Y; Chen S; Dou J; Wang Y; Yan S; Lu J; Chen H
    Eur Radiol; 2023 Dec; 33(12):9038-9051. PubMed ID: 37498380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Kondo M; Morimoto M; Numata K; Nozaki A; Tanaka K
    Jpn J Clin Oncol; 2011 Jan; 41(1):69-75. PubMed ID: 20688778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
    Kanekawa T; Nagai H; Kanayama M; Sumino Y
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):899-909. PubMed ID: 25138286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Zhuang BW; Li W; Xie XH; Hu HT; Lu MD; Xie XY
    Jpn J Clin Oncol; 2019 Sep; 49(9):845-855. PubMed ID: 31063184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.